Prof. Jacob Sten
DMSc, Corporate Vice President Global Drug Discovery,
Novo Nordisk A/S
Head of the Stem Cell R&D Transformational Research Unit
(Corporate Vice President), responsible for the entire R&D value
chain, from research, manufacturing for clinical de-velopment (CMC),
non-clinical, clinical development, regulatory and business
develop-ment, project management and operations.
2002-2018: Therapeutic area head for diabetes (type 1 and 2) and
stem cells in Global Research at Novo Nordisk. Previous areas of
responsibility in global research includes obesity and NASH. Previous
2001-2002: Executive Chief Scientific Officer Inoxell Inc. Denmark,
focusing on finding novel drug tar-gets.
1998-2001: Head of Islet Discovery Research, Novo Nordisk Denmark:
Working with type 2 and type 1 diabetes.
1995-1998: Senior scientist/project manager at ZymoGenetics inc.
Seattle USA: Work-ing on type 1 diabetes intervention/prevention and immunology.
1989-1995: Ph.D student and later Staff scientist Hagedorn Research
Institute, Gentofte Denmark: Research focus on islet biology and type
From 2010 professor in biomedicine at the medical faculty in
Copenhagen University. In 2006 awarded the doctor of medical science
(DMSc) degree from the medical faculty Copenhagen University Den-mark.
Member of the board of directors of JDRF Denmark (vice-chairman).
Besides numerous presentations at international diabetes
conferences, published approx. 60 papers in peered reviewed journals
mainly on topics of diabetes prediction, prevention and intervention
but also on beta cell biology, physiology and immunology.